321 related articles for article (PubMed ID: 28702718)
1. Single-Center Experience Using Selexipag in a Pediatric Population.
Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
[TBL] [Abstract][Full Text] [Related]
2. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
3. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
4. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
El Yafawi R; Wirth JA
Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
[TBL] [Abstract][Full Text] [Related]
5. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
6. Selexipag: First Global Approval.
Scott LJ
Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
[TBL] [Abstract][Full Text] [Related]
7. Oral treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Radosevich J; Dutt M
Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
[TBL] [Abstract][Full Text] [Related]
8. Selexipag: A Review in Pulmonary Arterial Hypertension.
Duggan ST; Keam SJ; Burness CB
Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
[TBL] [Abstract][Full Text] [Related]
9. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
10. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
11. Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Lafuente-Romero A; Rodriguez Ogando A
Cardiol Young; 2021 Sep; 31(9):1513-1515. PubMed ID: 33781364
[TBL] [Abstract][Full Text] [Related]
12. Selexipag for the treatment of pulmonary arterial hypertension.
Sharma K
Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
[TBL] [Abstract][Full Text] [Related]
13. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA; Chin KM
Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
15. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of selexipag for the treatment of pulmonary hypertension.
Panagiotidou E; Boutou A; Pitsiou G
Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
[TBL] [Abstract][Full Text] [Related]
18. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
19. Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L; Wacker J; Beghetti M; Lador F
Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
